BR0308221A - Derivados de tiazol e oxazol que modulam a atividade de ppar - Google Patents

Derivados de tiazol e oxazol que modulam a atividade de ppar

Info

Publication number
BR0308221A
BR0308221A BR0308221-0A BR0308221A BR0308221A BR 0308221 A BR0308221 A BR 0308221A BR 0308221 A BR0308221 A BR 0308221A BR 0308221 A BR0308221 A BR 0308221A
Authority
BR
Brazil
Prior art keywords
ppar activity
compounds
thiazole
oxazole derivatives
relates
Prior art date
Application number
BR0308221-0A
Other languages
English (en)
Inventor
Xue-Min Cheng
Noe Ouano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0308221A publication Critical patent/BR0308221A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE TIAZOL E OXAZOL QUE MODULAM A ATIVIDADE DE PPAR". A presente invenção refere-se a compostos que alteram a atividade de PPAR. A invenção também refere-se a sais farmaceuticamente aceitáveis de compostos, composições farmaceuticamente aceitáveis compreendendo os compostos ou seus sais, e métodos de empregá-los como agentes terapêuticos para tratamento ou prevenção de hiperlipidemia e hipercolesteremia em um mamífero. A presente invenção também refere-se a método para a preparação os compostos descritos.
BR0308221-0A 2002-03-07 2003-03-03 Derivados de tiazol e oxazol que modulam a atividade de ppar BR0308221A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240002P 2002-03-07 2002-03-07
PCT/IB2003/000817 WO2003074052A1 (en) 2002-03-07 2003-03-03 Thiazole and oxazole derivatives that modulate ppar activity

Publications (1)

Publication Number Publication Date
BR0308221A true BR0308221A (pt) 2005-01-04

Family

ID=27789156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308221-0A BR0308221A (pt) 2002-03-07 2003-03-03 Derivados de tiazol e oxazol que modulam a atividade de ppar

Country Status (29)

Country Link
US (1) US6833380B2 (pt)
EP (1) EP1485091A1 (pt)
JP (1) JP2005524665A (pt)
KR (1) KR20040091694A (pt)
CN (1) CN1638768A (pt)
AP (1) AP2004003123A0 (pt)
AR (1) AR038883A1 (pt)
AU (1) AU2003207891A1 (pt)
BR (1) BR0308221A (pt)
CA (1) CA2476580A1 (pt)
CO (1) CO5601013A2 (pt)
EA (1) EA200401160A1 (pt)
EC (1) ECSP045275A (pt)
GT (1) GT200300053A (pt)
HR (1) HRP20040810A2 (pt)
IL (1) IL163768A0 (pt)
IS (1) IS7399A (pt)
MA (1) MA27182A1 (pt)
MX (1) MXPA04008624A (pt)
NO (1) NO20044245L (pt)
OA (1) OA12781A (pt)
PA (1) PA8568701A1 (pt)
PE (1) PE20031010A1 (pt)
PL (1) PL372971A1 (pt)
TN (1) TNSN04167A1 (pt)
TW (1) TW200400027A (pt)
UY (1) UY27704A1 (pt)
WO (1) WO2003074052A1 (pt)
ZA (1) ZA200406491B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69720429T9 (de) 1996-02-02 2004-09-23 Merck & Co., Inc. Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6204277B1 (en) 1996-08-19 2001-03-20 Japan Tobacco Inc. Propionic acid derivatives and applications thereof
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DE60005973T2 (de) 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
HUP0300857A3 (en) 2000-08-23 2007-03-28 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7091225B2 (en) 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
CA2448639A1 (en) 2001-05-29 2002-12-05 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
EA200400011A1 (ru) 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
ATE394376T1 (de) 2001-06-18 2008-05-15 Ono Pharmaceutical Co Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
EP1435946B8 (en) 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
IL163768A0 (en) 2005-12-18
MA27182A1 (fr) 2005-01-03
CA2476580A1 (en) 2003-09-12
PA8568701A1 (es) 2003-11-12
PL372971A1 (en) 2005-08-08
GT200300053A (es) 2003-10-10
UY27704A1 (es) 2003-10-31
ECSP045275A (es) 2004-10-26
US6833380B2 (en) 2004-12-21
NO20044245L (no) 2004-10-06
MXPA04008624A (es) 2004-12-06
WO2003074052A1 (en) 2003-09-12
AU2003207891A1 (en) 2003-09-16
TNSN04167A1 (fr) 2007-03-12
TW200400027A (en) 2004-01-01
US20030207916A1 (en) 2003-11-06
OA12781A (en) 2006-07-07
CN1638768A (zh) 2005-07-13
AR038883A1 (es) 2005-02-02
PE20031010A1 (es) 2003-12-12
JP2005524665A (ja) 2005-08-18
CO5601013A2 (es) 2006-01-31
AP2004003123A0 (en) 2004-09-30
IS7399A (is) 2004-08-12
EA200401160A1 (ru) 2005-02-24
HRP20040810A2 (en) 2004-12-31
KR20040091694A (ko) 2004-10-28
ZA200406491B (en) 2006-05-31
EP1485091A1 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
BR0308221A (pt) Derivados de tiazol e oxazol que modulam a atividade de ppar
BR0308277A (pt) Derivados tiazol e oxazol que modulam a atividade de ppar
BR0308202A (pt) Tiazóis e oxazóis substituìdos que modulam a atividade de ppar
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
BR112021020372A2 (pt) Métodos de tratamento de linfoma não hodgkin ao usar 2-(2,6-dioxopiperidin-3-il)-4-((2-fluo ro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoin dolina-1,3-diona
DK2316831T3 (da) 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
BRPI0718714B8 (pt) arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
MX388198B (es) Nuevos derivados de fenilo.
BRPI0510095A (pt) tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
BR0112476A (pt) Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
BR0109703A (pt) Derivados de piperazina
DOP2003000620A (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparación
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
TW200420549A (en) Thiazole derivatives
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
BR112021026462A2 (pt) Composições e métodos para tratar distúrbios de cns
DE59802356D1 (de) Lagerstabile ophthalmische zusammensetzungen, umfassend diclofenac und ofloxacin
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BR0209930A (pt) Composto, composição farmacêutica, método para tratar doenças proliferativas, e, uso de um composto
BR0308162A (pt) Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
BRPI0409763A (pt) compostos de arila como moduladores de ppars, método de modulação, método de inibição da formação de adipócitos em um mamìfero, método de tratamento de uma doença ou uma condição modulada por ppar e composição farmacêutica
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
DK1968571T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater som neuroprotektive midler

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.